Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 1% Improvement Relative Risk Ventilation -8% ICU admission 0% Devos et al. NCT04429854 DAWn-plasma Conv. Plasma RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? RCT 483 patients in Belgium (May 2020 - January 2021) No significant difference in outcomes seen Devos et al., European Respiratory J., doi:10.1183/13993003.01724-2021 Favors conv. plasma Favors control
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
Devos et al., European Respiratory Journal, doi:10.1183/13993003.01724-2021, DAWn-plasma, NCT04429854 (history)
Devos et al., Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma, European Respiratory Journal, doi:10.1183/13993003.01724-2021, DAWn-plasma, NCT04429854
Aug 2021   Source   PDF  
  All Studies   Meta
RCT 489 hospitalized COVID-19 patients in Belgium, showing no significant difference in outcomes with convalescent plasma.
risk of death, 1.0% lower, HR 0.99, p = 0.98, treatment 320, control 163.
risk of mechanical ventilation, 8.0% higher, HR 1.08, p = 0.78, treatment 320, control 163.
risk of ICU admission, no change, HR 1.00, p = 1.00, treatment 320, control 163.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Devos et al., 26 Aug 2021, Randomized Controlled Trial, Belgium, peer-reviewed, 26 authors, study period 2 May, 2020 - 26 January, 2021, average treatment delay 7.0 days, trial NCT04429854 (history) (DAWn-plasma).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
Timothy Devos, Quentin Van Thillo, Veerle Compernolle, Tomé Najdovski, Marta Romano, Nicolas Dauby, Laurent Jadot, Mathias Leys, Evelyne Maillart, Sarah Loof, Lucie Seyler, Martial Moonen, Michel Moutschen, Niels Van Regenmortel, Kevin K Ariën, Cyril Barbezange, Albrecht Betrains, Mutien Garigliany, Matthias M Engelen, Iwein Gyselinck, Piet Maes, Alexander Schauwvlieghe, Laurens Liesenborghs, Ann Belmans, Peter Verhamme, Geert Meyfroidt
European Respiratory Journal, doi:10.1183/13993003.01724-2021
Early transfusion of 4 units of high neutralising antibody titre convalescent plasma in hospitalised COVID-19 patients does not reduce mortality or the need for mechanical ventilation 3fiRY2I
Abani, Abbas, Abbas, Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial, Lancet
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -final report, N Engl J Med
Betrains, Godinas, Woei-A-Jin, Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies, Br J Haematol
Devos, Geukens, Schauwvlieghe, A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial, Trials
Gharbharan, Jordans, Geurtsvankessel, Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection, Nat Commun
Goldberg, Zvi, Sheena, A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel, Clin Microbiol Infect
Grasselli, Pesenti, Cecconi, Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response, JAMA
Guimarães, Quirk, Furtado, Tofacitinib in patients hospitalized with Covid-19 pneumonia, N Engl J Med
Hueso, Pouderoux, Péré, Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19, Blood
Janiaud, Axfors, Schmitt, Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA
Joyner, Carter, Senefeld, Convalescent plasma antibody levels and the risk of death from Covid-19, N Engl J Med
Libster, Marc, Wappner, Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med
O'donnell, Grinsztejn, Cummings, A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19, J Clin Invest
Rubin, Multiple imputation after 18+ years, J Am Stat Assoc
Salama, Han, Yau, Tocilizumab in patients hospitalized with Covid-19 pneumonia, N Engl J Med
Simonovich, Pratx, Scibona, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med
Taccone, Van Goethem, Pauw, The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium, Lancet Reg Health Eur
The, Group, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
The, Investigators, Interleukin-6 receptor antagonists in critically ill patients with Covid-19, N Engl J Med
Verity, Okell, Dorigatti, Estimates of the severity of coronavirus disease 2019: a model-based analysis, Lancet Infect Dis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop